J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
BERKELEY, Calif., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at Oppenheimer’s 26th Annual Healthcare Conference in New York on Wednesday, December 9, 2015, at 9:45 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 [email protected]
